Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy
This study is being done to learn more about the short-term and long-term side effects of CAR-T cell therapy. Specifically, researchers want to know how often patients get infections, have delays in recovering blood cell counts and/or have damage to the nervous system.
Official registry: https://clinicaltrials.gov/study/NCT06579469 · St. Jude Children's Research Hospital · enrollment listed as 100
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 100 people at 7 sites. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy (PROSPER)
Primary outcome (registry wording): Presence of bone marrow dysfunction (BMD)
Who it is for (from inclusion criteria)
- Ages any to 30 Years
- Participants must have received an initial systemically-administered CAR T cell infusion for an oncologic diagnosis within the last 1-3 months (+/- 14 days)
- Initial infusion is defined as the first administration of a CAR T cell product the participant has not previously received OR receipt of a CAR T cell product previously received after an interval allogeneic HSCT
- Age ≤ 30 years at CAR T cell infusion
Who the registry excludes
- Active malignancy other than the disease under study
- Planned consolidative HSCT within 3 months post CAR T cell infusion
- Received or planned additional disease directed therapy post CAR T cell infusion
Public study contact (from the registry)
Rebecca Epperly, MD
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
7 listed- Children's Hospital Los Angeles — Los Angeles, California (recruiting)
- Childrens Hospital of Colorado — Aurora, Colorado (recruiting)
- Children's Hospital of Philadelphia — Philadelphia, Pennsylvania (recruiting)
- St. Jude Children's Research Hospital — Memphis, Tennessee (recruiting)
- Primary Children's Hospital — Salt Lake City, Utah (recruiting)
- Seattle Childrens Hospital — Seattle, Washington (recruiting)
- Children's Hospital of Wisconsin. — Milwaukee, Wisconsin (recruiting)
FAQ about this NCT record
Is NCT06579469 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06579469?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06579469?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary